A seminal review published in LabMed Discovery integrates recent advancements in metabolomics and microbiomics to elucidate the intricate pathophysiology of esophageal cancer.
Key insights include:
1) Metabolic Dysregulation: Tumor tissues demonstrate diminished fatty acid levels, elevated lysophosphatidylcholine concentrations, and an unexpected accumulation of citric acid—indicative of perturbed glucose and lipid metabolic pathways.
2) Microbiome Alterations: Dysbiosis in both gut and oral microbiota—particularly the enrichment of Fusobacterium nucleatum—is associated with tumor progression, resistance to chemotherapy, and unfavorable clinical outcomes.
3) Emerging Biomarkers: Distinct metabolite profiles and microbial signatures show significant potential for early detection and prognostic stratification.
The review emphasizes the value of multi-omics integration (metabolomics and microbiomics) in characterizing the tumor microenvironment. Innovations such as AI-driven metabolomic imaging and spatially resolved mass spectrometry are further enhancing analytical precision. Collectively, these developments are poised to inform the next generation of diagnostic strategies and therapeutic interventions targeting metabolic and microbial axes.
LabMed Discovery
News article
Review of Metabolomics and Microbiomics in Esophageal Cancer: From Pathogenesis to Prognosis
27-Feb-2025